Cargando…

Risk of overanticoagulation during acute kidney injury in patients treated with vitamin K antagonists

BACKGROUND: Vitamin K antagonists (VKAs) are still in use for oral anticoagulation, but not all indications allow their replacement by direct oral anticoagulants. Although formal dose reduction is not required in patients with impaired kidney function, case reports indicate that acute kidney injury...

Descripción completa

Detalles Bibliográficos
Autores principales:	Süfling, Luisa, Greinert, Daniel, Girndt, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951229/ https://www.ncbi.nlm.nih.gov/pubmed/33459792 http://dx.doi.org/10.1093/ndt/gfab008

Ejemplares similares

COVID-19 and acute kidney injury in German hospitals 2020
por: Walendy, Victor, et al.
Publicado: (2022)

Conservative Management of Overanticoagulation in Patients With Low–Moderate Risk for Bleeding Complications
por: Schapkaitz, Elise, et al.
Publicado: (2018)

Oliguric acute kidney injury as a main symptom of bradycardia and arteriosclerosis resolved by pacemaker implantation: a case report
por: Pliquett, Rainer U, et al.
Publicado: (2014)

Systemic inflammation in acute cardiorenal syndrome: an observational pilot study
por: Linhart, Christoph, et al.
Publicado: (2018)

Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage
por: Parry‐Jones, Adrian R., et al.
Publicado: (2015)

Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Effects of direct oral anticoagulants vs. vitamin K antagonists on acute kidney injury in patients with atrial fibrillation: A systematic review
por: Ren, Chengfa, et al.
Publicado: (2023)

Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery
por: Manfredini, Mattia, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
por: Laugesen, Emma Kirstine, et al.
Publicado: (2019)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
por: van der Meijden, Paola E. J., et al.
Publicado: (2013)

The impact of acute diarrhea on the coagulation status of patients with vitamin K antagonists
por: Schweinfurth, Johannes, et al.
Publicado: (2021)

Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease
por: Posch, Florian, et al.
Publicado: (2019)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation
por: Bukhari, Muhammad A, et al.
Publicado: (2019)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis
por: Yang, Kuang-Tsu, et al.
Publicado: (2020)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
por: van Heteren, D. Max, et al.
Publicado: (2022)

Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Is use of vitamin K antagonists associated with the risk of prostate cancer?: A meta-analysis
por: Luo, Jin-Dan, et al.
Publicado: (2018)

Vitamin C-induced Acute Kidney Injury
por: Bae, Eun Hui, et al.
Publicado: (2017)

Reversal of Vitamin K Antagonist Therapy by Prothrombin Complex Concentrate before Thrombolysis for Acute Stroke
por: Chausson, Nicolas, et al.
Publicado: (2013)

Geographic variation in the reversal of vitamin K antagonist-associated coagulopathy
por: Neal, M, et al.
Publicado: (2008)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Extent of arterial calcification by conventional vitamin K antagonist treatment
por: Hasific, Selma, et al.
Publicado: (2020)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study
por: Alikhan, Raza, et al.
Publicado: (2019)

Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
por: Reers, Stefan, et al.
Publicado: (2016)

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials
por: Caluwé, Rogier, et al.
Publicado: (2016)

Vitamin K antagonists and cardiovascular calcification: A systematic review and meta-analysis
por: Kosciuszek, Nina D., et al.
Publicado: (2022)

Vitamin K and Kidney Transplantation
por: Fusaro, Maria, et al.
Publicado: (2020)

Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
por: Ben Mbarka, F., et al.
Publicado: (2018)

Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing
por: Bloemen, Saartje, et al.
Publicado: (2017)

Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies
por: Anghel, Larisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_flfbam4h284066l7pbr289ob1r